CTLT240719C55000
- 1.75
- +0.15+9.38%
Catalent Newsroom
Unusual Options Activity: CTLT, STX and Others Attract Market Bets, CTLT V/OI Ratio Reaches 250.0
EST Jul 1st Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.O
Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating
11:52 AM EDT, 06/28/2024 (MT Newswires) -- Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating Price: 56.31, Change: -0.10, Percent Change: -0.19
Catalent Is Maintained at Equal-Weight by Barclays
Catalent Is Maintained at Equal-Weight by Barclays
Catalent Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 11.99% Barclays $47 → $63 Maintains Equal-Weight 04/04/2024 12.88% Stephens & Co. → $63.5 Reite
Express News | Catalent : Barclays Raises Target Price to $63 From $47
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Raises Target Price to $63
Barclays analyst Luke Sergott maintains $Catalent(CTLT.US)$ with a hold rating, and adjusts the target price from $47 to $63.According to TipRanks data, the analyst has a success rate of 40.5% and a t
Barclays Adjusts Catalent Price Target to $63 From $47
Catalent (CTLT) has an average rating of Hold and price targets ranging from $63 to $63.50, according to analysts polled by Capital IQ. Price: 56.57, Change: +0.41, Percent Change: +0.73
Sarepta Cut to Neutral at Citi on Risks to Valuation
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.
Catalent Gains After Sarepta's Elevidys Gets Label Expansion
Pharmaceutical Contract Manufacturing Market Report 2024-2030: Trends, Opportunities and Competitive Analysis Featuring Thermo Fisher Scientific, Catalent, Lonza, Almac Group, and Recipharm
Express News | Shares of Contract Drug Manufacturer Catalent up 3.3% After FDA's Expanded Use Nod for Sarepta's Duchenne Gene Therapy
Japan Contract Development Manufacturing Organization Market Report 2024-2030, Featuring Lonza, Recipharm, LabCorp, Catalent, WuXi AppTec, CordenPharma, Cambrex, Bushu Pharmaceuticals and Nipro
Just two shots a year, 100% effective! The market cap of the AIDS drug manufacturer soared by 48.3 billion.
The test results are impressive.
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $47
Barclays analyst Luke Sergott maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $47.According to TipRanks data, the analyst has a success rate of 42.3% and a total av
Ardena Appoints Jeremie Trochu as Chief Executive Officer
Ardena (the "Company") today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive...
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Topline Readout Expected in Q4 2024NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation,
Express News | NYSE Order Imbalance 740863.0 Shares on Sell Side
Catalent (NYSE:CTLT) Investors Are Sitting on a Loss of 47% If They Invested Three Years Ago
As an investor its worth striving to ensure your overall portfolio beats the market average.
Is Catalent (NYSE:CTLT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.'